Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?

Bibliography

• Talmud. Tractate Derech Eretz Zuta, Chapter I. Available from: http://www.jewishvirtuallibrary.org/jsource/Talmud/derecheretzruta1.html
   Google Scholar
• Terra JL. Suicide risk and depression. Rev Prat 2008;12(4):385-8
   Google Scholar
• Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev 2007;27(8):959-85
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095-105
   PubMed Web of Science ®Google Scholar
• Salzer HM, Lurie ML. Anxiety and depressive states treated with isonicotinyl hydrazide (isoniazid). AMA Arch Neurol Psychiatry 1953;70(3):317-24
   PubMedGoogle Scholar
• Scanlon WG, White WM. Iproniazid (marsilid): its use in office treatment of depression. Am J Psychiatry 1958;114(11):1036-7
   PubMed Web of Science ®Google Scholar
• Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 1958;115(5):459-64
   PubMed Web of Science ®Google Scholar
• Healy D. The three faces of the antidepressants: a critical commentary on the clinical-economic context of diagnosis. J Nerv Ment Dis 1999;187(3):174-80
   PubMed Web of Science ®Google Scholar
• Poe TE. Fluoxetine. A new antidepressant. N C Med J 1988;49(7):391-2
   PubMedGoogle Scholar
• Preskorn SH. CNS drug development. Part I: the early period of CNS drugs. J Psychiatr Pract 2010;16(5):334-9
   PubMed Web of Science ®Google Scholar
• Hanada K, Umemura S. Tricyclic antidepressants. Nippon Rinsho 2000;58(Suppl 2):633-7
   PubMedGoogle Scholar
• Howland RH. MAOI antidepressant drugs. J Psychosoc Nurs Ment Health Serv 2006;44(6):9-12
   Web of Science ®Google Scholar
• Baghai TC, Volz HP, Moller HJ. Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 2006;7(4):198-222
   PubMed Web of Science ®Google Scholar
• Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004;65(Suppl 4):5-10
   PubMed Web of Science ®Google Scholar
• Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001;3(1):22-7
   PubMedGoogle Scholar
• APA. Diagnostic and Statistical Manual for Mental Disorders, Third Revision (DSM-III-R). A.P. Association; Washington, DC: 1980
   Google Scholar
• APA. Diagnostic and Statistical Manual for Mental Disorders, Text Revision (DSM-IV-TR). 4th edition. American Psychiatric Association; Washington, DC: 2000
   Google Scholar
• Kennedy SH, Young AH, Blier P. Strategies to achieve clinical effectiveness: refining existing therapies and pursuing emerging targets. J Affect Disord 2011;132(Suppl 1):S21-8
   PubMedGoogle Scholar
• Serretti A. Antidepressants, present and future. Prog Neuropsychopharmacol Biol Psychiatry 2011;35(7):1531
   PubMed Web of Science ®Google Scholar
• Blier P. The well of novel antidepressants: running dry. J Psychiatry Neurosci 2010;35(4):219-20
   PubMed Web of Science ®Google Scholar
• Fornaro M, Giosue P. Current nosology of treatment resistant depression: a controversy resistant to revision. Clin Pract Epidemiol Ment Health 2010;6:20-4
   PubMedGoogle Scholar
• Pacchiarotti I, Mazzarini L, Colom F, Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009;120(6):429-40
   PubMed Web of Science ®Google Scholar
• Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122(5):509-22
   PubMed Web of Science ®Google Scholar
• Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1963;1(7272):79-81
   PubMed Web of Science ®Google Scholar
• McClure DJ. The role of dopamine in depression. Can Psychiatr Assoc J 1973;18(4):309012
   PubMedGoogle Scholar
• Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61(Suppl 6):4-6
   PubMed Web of Science ®Google Scholar
• Kicey CA. Catecholamines and depression: a physiological theory of depression. Am J Nurs 1974;74(11):2018-20
   PubMed Web of Science ®Google Scholar
• Nutt D, Demyttenaere K, Janka Z, The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007;21(5):461-71
   PubMed Web of Science ®Google Scholar
• Potter WZ, Manji HK. Catecholamines in depression: an update. Clin Chem 1994;40(2):279-87
   PubMed Web of Science ®Google Scholar
• Sulser F, Vetulani J, Mobley PL. Mode of action of antidepressant drugs. Biochem Pharmacol 1978;27(3):257-61
   PubMed Web of Science ®Google Scholar
• Wade A, Friis Andersen H. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 2006;22(11):2101-10
   PubMed Web of Science ®Google Scholar
• Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981;38(10):1160-80
   PubMed Web of Science ®Google Scholar
• Werner FM, Covenas R. Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci 2010;120(7):455-70
   PubMed Web of Science ®Google Scholar
• Wager-Smith K, Markou A. Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci Biobehav Rev 2011;35(3):742-64
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI. Neurotransmitters, neurosteroids and neurotrophins: new models of the pathophysiology and treatment of depression. World J Biol Psychiatry 2003;4(3):98-102
   PubMed Web of Science ®Google Scholar
• Baldwin DS. Where is the room for improvement in the drug treatment of depression and anxiety? Hum Psychopharmacol 2011;26(1):1-3
   PubMed Web of Science ®Google Scholar
• Nierenberg AA. Antidepressants: can't live with them, can't live without them. CNS Spectr 2010;15(3):146-7
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals 2010;3:19-41
   Google Scholar
• Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153(2):151-62
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Salvadore G, Luckenbaugh DA, Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 2008;69(6):946-58
   PubMed Web of Science ®Google Scholar
• Payne JL, Quiroz JA, Zarate CA Jr, Manji HK. Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry 2002;52(10):921-6
   PubMed Web of Science ®Google Scholar
• Tome MB, Cloninger CR, Watson JP, Isaac MT. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. J Affect Disord 1997;44(2-3):101-9
   PubMed Web of Science ®Google Scholar
• Kaneda A, Yasui-Furukori N, Nakagami T, The influence of personality factors on paroxetine response time in patients with major depression. J Affect Disord 2011
   Web of Science ®Google Scholar
• Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001;15(10):765-76
   PubMed Web of Science ®Google Scholar
• Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010;8(3):287-304
   PubMed Web of Science ®Google Scholar
• Catena-Dell’Osso M, Bellantuono C, Consoli G, Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 2011;18(2):245-55
   PubMed Web of Science ®Google Scholar
• Chopra K, Kumar B, Kuhad A. Pathobiological targets of depression. Expert Opin Ther Targets 2011;15(4):379-400
   PubMed Web of Science ®Google Scholar
• Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides 2005;26(8):1383-93
   PubMed Web of Science ®Google Scholar
• Blier P, Gobbi G, Haddjeri N, Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 2004;29(3):208-18
   PubMed Web of Science ®Google Scholar
• Mansvelder HD, Mertz M, Role LW. Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits. Semin Cell Dev Biol 2009;20(4):432-40
   PubMed Web of Science ®Google Scholar
• Lebowitz B, Harris HW. Drug discovery and mental illness. Dialogues Clin Neurosci 2002;4:325-8
   PubMedGoogle Scholar
• Van Praag HM. State of the art. The impact of classification on psychopharmacology and biological psychiatry. Dialogues Clin Neurosci 2003;1:141-9
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Bech P. Rating sales in depression: limitations and pitfalls. Dialogues Clin Neurosci 2006;8(2):207-15
   PubMedGoogle Scholar
• Benazzi F. Various forms of depression. Dialogues Clin Neurosci 2006;8(2):151-61
   PubMedGoogle Scholar
• Fava M, Rush AJ, Trivedi MH, Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003;26(2):457-94, x
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Results of the STAR*D study: implications for clinicians and drug developers. J Psychiatr Pract 2009;15(1):45-9
   PubMed Web of Science ®Google Scholar
• Trivedi RB, Nieuwsma JA, Williams JW Jr. Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. J Gen Intern Med 2011;26(6):643-50
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Fava M, Trivedi MH, A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163(9):1519-30; quiz 1665
   PubMed Web of Science ®Google Scholar
• O’Reardon JP. Pharmacologic and therapeutic strategies in treatment-resistant depression. Introduction and clinical presentations. CNS Spectr 2009;14(3 Suppl 4):4-6
   PubMed Web of Science ®Google Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166(9):980-91
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova A, Mori N, Keck PE Jr. Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opin Investig Drugs 2010;19(12):1527-44
   PubMed Web of Science ®Google Scholar
• Tohen M, Case M, Trivedi MH, Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010;71(4):451-62
   PubMed Web of Science ®Google Scholar
• Mathews J, Garcia KS, Mintun MA, Sheline YI. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study. Psychiatry Res 2006;146(2):149-55
   PubMed Web of Science ®Google Scholar
• Mitchell PB, Goodwin GM, Johnson GF, Hirschfeld RM. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord 2008;10(1 Pt 2):144-52
   PubMed Web of Science ®Google Scholar
• Perlis RH, Uher R, Ostacher M, Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry 2011;68(4):351-60
   PubMed Web of Science ®Google Scholar
• Sachs GS, Thase ME, Otto MW, Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003;53(11):1028-42
   PubMed Web of Science ®Google Scholar
• Ghaemi SN. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disord 2008;10(8):957-68
   PubMed Web of Science ®Google Scholar
• Vazquez G, Tondo L, Baldessarini RJ. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: a meta-analytic review. Pharmacopsychiatry 2011;44(1):21-6
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Rosenquist KJ, Ko JY, Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004;161(1):163-5
   PubMed Web of Science ®Google Scholar
• Kora K, Kaplan P. Hypomania/mania induced by cessation of antidepressant drugs. Turk Psikiyatri Derg 2008;19(3):329-33
   PubMed Web of Science ®Google Scholar
• Rihmer Z, Gonda X. Antidepressant-resistant depression and antidepressant-associated suicidal behaviour: the role of underlying bipolarity. Depress Res Treat 2011;2011:906462
   PubMedGoogle Scholar
• El-Mallakh RS, Ghaemi SN, Sagduyu K, Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord 2008;111(2-3):372-7
   PubMed Web of Science ®Google Scholar
• Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 2006;94(1-3):3-13
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Ko JY, Goodwin FK. The bipolar spectrum and the antidepressant view of the world. J Psychiatr Pract 2001;7(5):287-97
   PubMedGoogle Scholar
• Hirschfeld RM, Williams JB, Spitzer RL, Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000;157(11):1873-5
   PubMed Web of Science ®Google Scholar
• Kiejna A, Rymaszewska J, Hadryś T, Bipolar or unipolar? – the question for clinicians and researchers. J Affect Disord 2006;93(1-3):177-83
   PubMed Web of Science ®Google Scholar
• Angst J, Gamma A, Bowden CL, Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci 2011 Aug 5. [Epub ahead of print]
   Web of Science ®Google Scholar
• Angst J, Azorin JM, Bowden CL, Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry 2011;68(8):791-8
   PubMed Web of Science ®Google Scholar
• Chun BJ, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord 2004;6(1):32-42
   PubMed Web of Science ®Google Scholar
• Akiskal HS, Mallya G. Criteria for the ‘soft’ bipolar spectrum: treatment implications. Psychopharmacol Bull 1987;23(1):68-73
   PubMedGoogle Scholar
• Kaye NS. Is your depressed patient bipolar? J Am Board Fam Pract 2005;18(4):271-81
   PubMedGoogle Scholar
• Perugi G, Akiskal HS, Lattanzi L, The high prevalence of ‘soft’ bipolar (II) features in atypical depression. Compr Psychiatry 1998;39(2):63-71
   PubMed Web of Science ®Google Scholar
• Warden D, Rush AJ, Wisniewski SR, What predicts attrition in second step medication treatments for depression?: a STAR*D Report. Int J Neuropsychopharmacol 2009;12(4):459-73
   PubMed Web of Science ®Google Scholar
• Lucae S, HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 2010;20(1):65-8
   PubMed Web of Science ®Google Scholar
• Perugi G, Fornaro M, Akiskal HS, Are atypical depression, borderline personality disorder and bipolar II disorder overlapping manifestations of a common cyclothymic diathesis? World Psychiatry 2011;10(1):45-51
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord 1999;52(1-3):135-44
   PubMed Web of Science ®Google Scholar
• Posternak MA, Zimmerman M. How accurate are patients in reporting their antidepressant treatment history? J Affect Disord 2003;75(2):115-24
   PubMed Web of Science ®Google Scholar
• Perlis RH. Can single genes matter in a polygenic world? Biol Psychiatry 2010;68(9):783-4
   PubMed Web of Science ®Google Scholar
• Duffy A, The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry 2000;61(9):630-7
   PubMed Web of Science ®Google Scholar
• Purcell SM, Wray NR, Stone JL, International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460(7256):748-52
   PubMed Web of Science ®Google Scholar
• Perlis RH. Betting on biomarkers. Am J Psychiatry 2011;168(3):234-6
   PubMed Web of Science ®Google Scholar
• Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004;29(10):1765-81
   PubMed Web of Science ®Google Scholar
• Zou YF, Ye DQ, Feng XL, Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 2010;20(8):535-44
   PubMed Web of Science ®Google Scholar
• Domschke K, Dannlowski U, Hohoff C, Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 2010;20(5):301-9
   PubMed Web of Science ®Google Scholar
• Keers R, Bonvicini C, Scassellati C, Variation in GNB3 predicts response and adverse reactions to antidepressants. J Psychopharmacol 2011;25(7):867-74
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):593-602
   PubMed Web of Science ®Google Scholar
• Nierenberg AA. The perfect storm: CNS drug development in trouble. CNS Spectr 2010;15(5):282-3
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. Bipolar depression: the real challenge. Eur Neuropsychopharmacol 2004;14(Suppl 2):S83-8
   PubMedGoogle Scholar
• Ghaemi SN, Ko JY, Goodwin FK. ‘Cade's disease’ and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002;47(2):125-34
   PubMed Web of Science ®Google Scholar
• Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998;50(2-3):143-51
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Calabrese JR, Weissman MM, Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64(1):53-9
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59(6):530-7
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Frank E, Grochocinski VJ, Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002;63(2):120-5
   PubMed Web of Science ®Google Scholar
• Sachs GS, Yan LJ, Swann AC, Allen MH. Integration of suicide prevention into outpatient management of bipolar disorder. J Clin Psychiatry 2001;62(Suppl 25):3-11
   PubMedGoogle Scholar
• Meyer RE, Salzman C, Youngstrom EA, Suicidality and risk of suicide–definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 2010;71(8):e1-e21
   PubMed Web of Science ®Google Scholar
• Ghaemi SN. Toward a hippocratic psychopharmacology. Can J Psychiatry 2008;53(3):189-96
   PubMed Web of Science ®Google Scholar
• Angst J, Marneros A. Bipolarity from ancient to modern times: conception, birth and rebirth. J Affect Disord 2001;67(1-3):3-19
   PubMed Web of Science ®Google Scholar
• Faravelli C, Gorini Amedei S, Scarpato MA, Faravelli L. Bipolar disorder: an impossible diagnosis. Clin Pract Epidemiol Ment Health 2009;5:13
   PubMedGoogle Scholar
• Hirschfeld RM. Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiatry 2001;62(Suppl 14):5-9
   PubMedGoogle Scholar
• Fekadu A, What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord 2009;116(1-2):4-11
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry 2003;53(8):640-8
   PubMed Web of Science ®Google Scholar
• Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52(1):46-54
   PubMed Web of Science ®Google Scholar
• Schultz P. Are all antidepressants alike? Dialogues Clin Neurosci 1999;1(1):4-11
   PubMedGoogle Scholar
• WHO. International Classifical of Diseases (ICD-10). 10th edition. WHO; 1992
   Google Scholar
• van Praag HM. Nosologomania: a disorder of psychiatry. World J Biol Psychiatry 2000;1(3):151-8
   PubMedGoogle Scholar
• Kendler KS, Munoz RA, Murphy G. The development of the Feighner criteria: a historical perspective. Am J Psychiatry 2010;167(2):134-42
   PubMed Web of Science ®Google Scholar
• Akiskal HS. Validating ‘hard’ and ‘soft’ phenotypes within the bipolar spectrum: continuity or discontinuity? J Affect Disord 2003;73(1-2):1-5
   PubMed Web of Science ®Google Scholar
• Maremmani I, Perugi G, Pacini M, Akiskal HS. Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord 2006;93(1-3):1-12
   PubMed Web of Science ®Google Scholar
• Oedegaard KJ, Greenwood TA, Johansson S, A genome-wide association study of bipolar disorder and comorbid migraine. Genes Brain Behav 2010;9(7):673-80
   PubMed Web of Science ®Google Scholar
• McElroy SL, Kotwal R, Keck PE Jr, Akiskal HS. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Disord 2005;86(2-3):107-27
   PubMed Web of Science ®Google Scholar
• Lucas MC, Weikert RJ, Carter DS, Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain. Bioorg Med Chem Lett 2010;20(18):5559-66
   PubMed Web of Science ®Google Scholar
• Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: the next generation of antidepressants. Curr Neuropharmacol 2008;6(4):338-43
   PubMed Web of Science ®Google Scholar
• Stahl S. editor. Stahl's essential psychopharmacology. 3rd edition. Neuroscientific Basis and Practical Applications; Cambridge: San Diego: 2008
   Google Scholar
• Kamiyama H, Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway. Neuroscience 2011;177:159-69
   PubMed Web of Science ®Google Scholar
• Wulsin AC, Herman JP, Solomon MB. Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress. Psychoneuroendocrinology 2010;35(7):1100-12
   PubMed Web of Science ®Google Scholar
• Breuer ME, SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model. Naunyn Schmiedebergs Arch Pharmacol 2009;379(1):101-6
   PubMed Web of Science ®Google Scholar
• Davies J, CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity for [3H]D-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res 1986;382(1):169-73
   PubMed Web of Science ®Google Scholar
• Jordan GR, Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography. Neuropharmacology 2005;49(2):254-64
   PubMed Web of Science ®Google Scholar
• Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. Depress Anxiety 2007;24(7):495-517
   PubMed Web of Science ®Google Scholar
• Borsook D, GABA and circadian timekeeping: implications for manic-depression and sleep disorders. Med Hypotheses 1986;19(2):185-98
   PubMed Web of Science ®Google Scholar
• Nurnberg HG, Seidman SN, Gelenberg AJ, Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology 2002;60(2 Suppl 2):58-66
   PubMed Web of Science ®Google Scholar
• Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacol Biochem Behav 2008;89(4):623-6
   PubMed Web of Science ®Google Scholar
• Stahl SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry 2008;69(11):1673-4
   PubMed Web of Science ®Google Scholar
• Naidu PS, Varvel SA, Ahn K, Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 2007;192(1):61-70
   PubMed Web of Science ®Google Scholar
• Chen CY, Tzeng NS, Chen YC. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen Hosp Psychiatry 2010;32(6):647; e7-9
   PubMedGoogle Scholar
• O’Donovan C, Garnham JS, Hajek T, Alda M. Antidepressant monotherapy in pre-bipolar depression; predictive value and inherent risk. J Affect Disord 2008;107(1-3):293-8
   PubMed Web of Science ®Google Scholar
• Gan Z, Diao F, Wei Q, A predictive model for diagnosing bipolar disorder based on the clinical characteristics of major depressive episodes in Chinese population. J Affect Disord 2011
   Web of Science ®Google Scholar
• King M, Development and validation of an international risk prediction algorithm for episodes of major depression in general practice attendees: the PredictD study. Arch Gen Psychiatry 2008;65(12):1368-76
   PubMed Web of Science ®Google Scholar
• Bondolfi G, Aubry JM, Golaz J, A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med Wkly 2006;136(5-6):78-85
   PubMed Web of Science ®Google Scholar
• Ricken R, Wiethoff K, Reinhold T, Algorithm-guided treatment of depression reduces treatment costs – Results from the randomized controlled German Algorithm Project (GAPII). J Affect Disord 2011
   Google Scholar
• Bauer M, Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol 2009;29(4):327-33
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61(7):669-80
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Croft HA, Gossen ER, Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgmont) 2009;6(5):20-33
   PubMedGoogle Scholar
• Pae CU. Desvenlafaxine: a new antidepressant or just another one? Expert Opin Pharmacother 2009;10(5):875-87
   PubMed Web of Science ®Google Scholar
• Adell A. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. IDrugs 2010;13(12):900-10
   PubMedGoogle Scholar
• Howland RH. Vilazodone: another novel atypical antidepressant drug. J Psychosoc Nurs Ment Health Serv 2011;49(3):19-22
   PubMed Web of Science ®Google Scholar
• Feiger AD, Heiser JF, Shrivastava RK, Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003;64(3):243-9
   PubMed Web of Science ®Google Scholar
• de Paulis T. Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression. Curr Opin Investig Drugs 2007;8(1):78-86
   PubMedGoogle Scholar
• Bermack JE, Debonnel G. Effects of OPC-14523, a combined sigma and 5-HT1a ligand, on pre- and post-synaptic 5-HT1a receptors. J Psychopharmacol 2007;21(1):85-92. Epub 2006 Mar 13
   PubMed Web of Science ®Google Scholar
• Lifschytz T, Segman R, Shalom G, Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets 2006;7(2):203-10
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354(12):1231-42
   PubMed Web of Science ®Google Scholar